Check out these photos from today’s Paragraph IV Disputes Conference. www.AmericanConference.com/PIVDisputes
Check out all of the highlights from ACI’s 9th Annual Paragraph IV Disputes
Complimentary presentation from ACI’s 2nd Annual Paragraph IV Disputes Master Symposium. Highlights from this presentation: – Inequitable conduct post Therasense – Adoption of Therasense standard – PTO rules of professional conduct – Obligations within Hatch-Waxman context and much more…
Expert article by Joseph E. Cwik on May 27, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. Several parts of the America Invents Act (the “AIA”) became law on Sept. 16, 2012, sparking some of the most meaningful changes to patent law seen in decades. One hot provision…
Expert article by Joseph E. Cwik and Josh Nosal on July 2, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. The Patent Trial and Appeal Board (PTAB) issued its first final written decisions June 20, 2014, in four inter partes reviews (IPR) of pharmaceutical-related patents. The four decisions…
April was a productive month for ACI’s conference attendees. At our events, decision makers had the chance to acquire top notch industry information; ranging from the latest trends, developments, hottest litigation cases to key insights from leading experts and more. You now have the opportunity to remain ahead of the curve too by accessing conference materials.…
ACI’s 8th Annual Paragraph IV Dispute took place earlier this year in New York. We asked speakers to share their best practices for a complimentary e-book.Don’t miss out on valuable insights from Christopher R. Noyes, David A. Manspeizer, Paul A. Ragusa, and Stephen R. Auten.
Expert Guest Entry by Paul Ragusa, Originally published on Law 360 The terms “product switching,” “product hopping” and “line extension” are often used to describe the strategy of protecting market share by reformulating or otherwise modifying an existing branded pharmaceutical product in a manner which requires approval from the U.S. Food and Drug Administration. Under this…
Pharma & Healthcare – this week’s update includes Coloplast’s $16 million lawsuit, FDA issues referrals letters and more.
Pharma & Healthcare – the latest on FDA’s proposed generic drug labeling rule, FDA bans imports from India’s Sun Pharma and more.
Pharma & Healthcare – the latest on Takeda Pharmaceutical improper drug ads, FDA spying and more. FDA spying may have broken whistleblower laws, congressional probe finds by Arlene Weintraub Published on FiercePharma Two years after press reports revealed that the FDA was extensively monitoring communications by some of its employees, a congressional committee has wrapped up its investigation.…
Master the litigation strategies that your company needs to successfully scale the legal intricacies of this next crag of the patent cliff When: Tuesday, May 07 to Wednesday, May 08, 2013 Where: Crowne Plaza Times Square Manhattan, New York, NY For more information, and to register: click here Industry Related News Industry related article from…